CIA BRASILEIRA DE DIS- ADR (CBD) Fundamental Analysis & Valuation

NYSE:CBD • US20440T3005

Current stock price

0.445 USD
-0.01 (-3.05%)
At close:
0.4357 USD
-0.01 (-2.09%)
After Hours:

This CBD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. CBD Profitability Analysis

1.1 Basic Checks

  • In the past year CBD has reported negative net income.
  • In the past year CBD had a positive cash flow from operations.
  • In multiple years CBD reported negative net income over the last 5 years.
  • Of the past 5 years CBD 4 years had a positive operating cash flow.
CBD Yearly Net Income VS EBIT VS OCF VS FCFCBD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 2B -2B 4B

1.2 Ratios

  • CBD has a worse Return On Assets (-10.30%) than 78.05% of its industry peers.
  • The Return On Equity of CBD (-48.12%) is worse than 80.49% of its industry peers.
  • With a Return On Invested Capital value of 0.48%, CBD is not doing good in the industry: 70.73% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -10.3%
ROE -48.12%
ROIC 0.48%
ROA(3y)-3.02%
ROA(5y)-0.73%
ROE(3y)-14.58%
ROE(5y)-4.12%
ROIC(3y)N/A
ROIC(5y)N/A
CBD Yearly ROA, ROE, ROICCBD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 -20 -40

1.3 Margins

  • CBD has a Operating Margin of 0.50%. This is in the lower half of the industry: CBD underperforms 68.29% of its industry peers.
  • CBD's Operating Margin has declined in the last couple of years.
  • The Gross Margin of CBD (25.02%) is better than 63.41% of its industry peers.
  • In the last couple of years the Gross Margin of CBD has remained more or less at the same level.
Industry RankSector Rank
OM 0.5%
PM (TTM) N/A
GM 25.02%
OM growth 3Y-54.5%
OM growth 5Y-37.57%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.29%
GM growth 5Y1.26%
CBD Yearly Profit, Operating, Gross MarginsCBD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. CBD Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CBD is destroying value.
  • Compared to 1 year ago, CBD has about the same amount of shares outstanding.
  • Compared to 1 year ago, CBD has a worse debt to assets ratio.
CBD Yearly Shares OutstandingCBD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M
CBD Yearly Total Debt VS Total AssetsCBD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 20B 40B 60B

2.2 Solvency

  • CBD has an Altman-Z score of 1.07. This is a bad value and indicates that CBD is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of CBD (1.07) is worse than 73.17% of its industry peers.
  • CBD has a Debt/Equity ratio of 1.72. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of CBD (1.72) is worse than 82.93% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.72
Debt/FCF N/A
Altman-Z 1.07
ROIC/WACC0.09
WACC5.48%
CBD Yearly LT Debt VS Equity VS FCFCBD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 1.21 indicates that CBD should not have too much problems paying its short term obligations.
  • CBD's Current ratio of 1.21 is in line compared to the rest of the industry. CBD outperforms 51.22% of its industry peers.
  • CBD has a Quick Ratio of 1.21. This is a bad value and indicates that CBD is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a decent Quick ratio value of 0.89, CBD is doing good in the industry, outperforming 70.73% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.21
Quick Ratio 0.89
CBD Yearly Current Assets VS Current LiabilitesCBD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 10B 20B 30B 40B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. CBD Growth Analysis

3.1 Past

  • The earnings per share for CBD have decreased strongly by -1171.43% in the last year.
  • Looking at the last year, CBD shows a very negative growth in Revenue. The Revenue has decreased by -59.86% in the last year.
  • CBD shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -17.17% yearly.
EPS 1Y (TTM)-1171.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.55%
Revenue 1Y (TTM)-59.86%
Revenue growth 3Y-27.85%
Revenue growth 5Y-17.17%
Sales Q2Q%-69.65%

3.2 Future

  • The Earnings Per Share is expected to grow by 24.83% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 8.97% on average over the next years. This is quite good.
EPS Next Y83.74%
EPS Next 2Y38.43%
EPS Next 3Y24.83%
EPS Next 5YN/A
Revenue Next Year8.97%
Revenue Next 2Y6.92%
Revenue Next 3Y6.72%
Revenue Next 5Y8.97%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CBD Yearly Revenue VS EstimatesCBD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20B 40B 60B 80B
CBD Yearly EPS VS EstimatesCBD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 2 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

1

4. CBD Valuation Analysis

4.1 Price/Earnings Ratio

  • CBD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CBD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CBD Price Earnings VS Forward Price EarningsCBD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

  • 85.37% of the companies in the same industry are more expensive than CBD, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 5
CBD Per share dataCBD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CBD's earnings are expected to grow with 24.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.43%
EPS Next 3Y24.83%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. CBD Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 13.41%, CBD is a good candidate for dividend investing.
  • In the last 3 months the price of CBD has falen by -47.63%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
  • Compared to an average industry Dividend Yield of 0.71, CBD pays a better dividend. On top of this CBD pays more dividend than 100.00% of the companies listed in the same industry.
  • CBD's Dividend Yield is rather good when compared to the S&P500 average which is at 1.88.
Industry RankSector Rank
Dividend Yield 13.41%

5.2 History

  • The dividend of CBD decreases each year by -24.04%.
  • CBD has paid a dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)-24.04%
Div Incr Years0
Div Non Decr Years0
CBD Yearly Dividends per shareCBD Yearly Dividends per shareYearly Dividends per share 2016 2018 2019 2020 2021 2022 0.5 1 1.5 2

5.3 Sustainability

  • The earnings of CBD are negative and hence is the payout ratio. CBD will probably not be able to sustain this dividend level.
DP-4.93%
EPS Next 2Y38.43%
EPS Next 3Y24.83%
CBD Yearly Income VS Free CF VS DividendCBD Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 0 1B -1B 2B -2B

More info and screens

Find the best dividend stocksShow peers with best dividend

CBD Fundamentals: All Metrics, Ratios and Statistics

CIA BRASILEIRA DE DIS- ADR

NYSE:CBD (4/18/2024, 8:04:00 PM)

After market: 0.4357 -0.01 (-2.09%)

0.445

-0.01 (-3.05%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupConsumer Staples Distribution & Retail
GICS IndustryConsumer Staples Distribution & Retail
Earnings (Last)02-21
Earnings (Next)05-01
Inst Owners0.12%
Inst Owner Change-2.09%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap218.06M
Revenue(TTM)19.25B
Net Income(TTM)-2.27B
Analysts50
Price Target1.53 (243.82%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 13.41%
Yearly Dividend0.41
Dividend Growth(5Y)-24.04%
DP-4.93%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-273.86%
Min EPS beat(2)-455.83%
Max EPS beat(2)-91.89%
EPS beat(4)0
Avg EPS beat(4)-228.76%
Min EPS beat(4)-455.83%
Max EPS beat(4)-25.58%
EPS beat(8)0
Avg EPS beat(8)-362.44%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.9%
Min Revenue beat(2)-4.34%
Max Revenue beat(2)-3.47%
Revenue beat(4)0
Avg Revenue beat(4)-27.12%
Min Revenue beat(4)-59.79%
Max Revenue beat(4)-3.47%
Revenue beat(8)2
Avg Revenue beat(8)-9.38%
Revenue beat(12)3
Avg Revenue beat(12)-9.97%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-19.66%
PT rev (3m)-10.73%
EPS NQ rev (1m)54.81%
EPS NQ rev (3m)58.85%
EPS NY rev (1m)49.53%
EPS NY rev (3m)46.14%
Revenue NQ rev (1m)-0.72%
Revenue NQ rev (3m)-1.13%
Revenue NY rev (1m)0.22%
Revenue NY rev (3m)-1.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.06
P/FCF N/A
P/OCF 1.99
P/B 0.24
P/tB 0.41
EV/EBITDA 5
EPS(TTM)-0.86
EYN/A
EPS(NY)-0.14
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)0.22
OCFY50.28%
SpS7.65
BVpS1.88
TBVpS1.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -10.3%
ROE -48.12%
ROCE 0.61%
ROIC 0.48%
ROICexc 0.63%
ROICexgc 0.76%
OM 0.5%
PM (TTM) N/A
GM 25.02%
FCFM N/A
ROA(3y)-3.02%
ROA(5y)-0.73%
ROE(3y)-14.58%
ROE(5y)-4.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-58.82%
ROICexgc growth 5Y-42.48%
ROICexc growth 3Y-57.55%
ROICexc growth 5Y-42.78%
OM growth 3Y-54.5%
OM growth 5Y-37.57%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.29%
GM growth 5Y1.26%
F-Score2
Asset Turnover0.87
Health
Industry RankSector Rank
Debt/Equity 1.72
Debt/FCF N/A
Debt/EBITDA 6.59
Cap/Depr 103.08%
Cap/Sales 6.08%
Interest Coverage 250
Cash Conversion 45.66%
Profit Quality N/A
Current Ratio 1.21
Quick Ratio 0.89
Altman-Z 1.07
F-Score2
WACC5.48%
ROIC/WACC0.09
Cap/Depr(3y)82.81%
Cap/Depr(5y)104.8%
Cap/Sales(3y)7.75%
Cap/Sales(5y)7.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1171.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.55%
EPS Next Y83.74%
EPS Next 2Y38.43%
EPS Next 3Y24.83%
EPS Next 5YN/A
Revenue 1Y (TTM)-59.86%
Revenue growth 3Y-27.85%
Revenue growth 5Y-17.17%
Sales Q2Q%-69.65%
Revenue Next Year8.97%
Revenue Next 2Y6.92%
Revenue Next 3Y6.72%
Revenue Next 5Y8.97%
EBIT growth 1Y-87.1%
EBIT growth 3Y-67.17%
EBIT growth 5Y-48.29%
EBIT Next Year586.28%
EBIT Next 3Y102.85%
EBIT Next 5Y76.66%
FCF growth 1Y66.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y360.65%
OCF growth 3Y-50.85%
OCF growth 5Y-33.31%

CIA BRASILEIRA DE DIS- ADR / CBD Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for CIA BRASILEIRA DE DIS- ADR?

ChartMill assigns a fundamental rating of 2 / 10 to CBD.


What is the valuation status for CBD stock?

ChartMill assigns a valuation rating of 1 / 10 to CIA BRASILEIRA DE DIS- ADR (CBD). This can be considered as Overvalued.


What is the profitability of CBD stock?

CIA BRASILEIRA DE DIS- ADR (CBD) has a profitability rating of 2 / 10.


What is the earnings growth outlook for CIA BRASILEIRA DE DIS- ADR?

The Earnings per Share (EPS) of CIA BRASILEIRA DE DIS- ADR (CBD) is expected to grow by 83.74% in the next year.


Is the dividend of CIA BRASILEIRA DE DIS- ADR sustainable?

The dividend rating of CIA BRASILEIRA DE DIS- ADR (CBD) is 5 / 10 and the dividend payout ratio is -4.93%.